MAVYRET ™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C

MAVYRET ™ (glecaprevir/pibrentasvir) was developed by US-based biopharmaceutical company AbbVie as a pan-genotypic treatment for adults suffering from chronic hepatitis C virus (HCV) infection across six major genotypes (GT1 to GT6).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news